TriSalus Life Sciences, Inc./$TLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Ticker
$TLSI
Sector
Primary listing
Employees
102
Headquarters
Website
TLSI Metrics
BasicAdvanced
$236M
-
-$1.84
0.44
-
Price and volume
Market cap
$236M
Beta
0.44
52-week high
$7.95
52-week low
$3.42
Average daily volume
203K
Financial strength
Current ratio
2.804
Quick ratio
2.348
Long term debt to equity
-101.22
Total debt to equity
-101.713
Interest coverage (TTM)
-4.86%
Profitability
EBITDA (TTM)
-26.32
Gross margin (TTM)
84.57%
Net profit margin (TTM)
-86.88%
Operating margin (TTM)
-59.68%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-56.80%
Return on equity (TTM)
131.29%
Valuation
Price to revenue (TTM)
3.232
Price to book
-5.68
Price to tangible book (TTM)
-5.68
Price to free cash flow (TTM)
-7.708
Free cash flow yield (TTM)
-12.97%
Free cash flow per share (TTM)
-0.5
Growth
Revenue change (TTM)
53.41%
Earnings per share change (TTM)
40.17%
3-year revenue growth (CAGR)
53.85%
3-year earnings per share growth (CAGR)
-77.50%
TLSI News
AllArticlesVideos
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
Business Wire·2 days ago
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TriSalus Life Sciences, Inc. stock?
TriSalus Life Sciences, Inc. (TLSI) has a market cap of $236M as of March 20, 2026.
What is the P/E ratio for TriSalus Life Sciences, Inc. stock?
The price to earnings (P/E) ratio for TriSalus Life Sciences, Inc. (TLSI) stock is 0 as of March 20, 2026.
Does TriSalus Life Sciences, Inc. stock pay dividends?
No, TriSalus Life Sciences, Inc. (TLSI) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next TriSalus Life Sciences, Inc. dividend payment date?
TriSalus Life Sciences, Inc. (TLSI) stock does not pay dividends to its shareholders.
What is the beta indicator for TriSalus Life Sciences, Inc.?
TriSalus Life Sciences, Inc. (TLSI) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.